A Phase III, randomized, open-label study comparing BNT324 with docetaxel plus prednisone/prednisolone in patients with castration-resistant metastatic prostate cancer.
Principal Investigator
Dott.ssa Alessandra Mosca
Contact Information for Access
Phase
FASE III
Status
IN ATTIVAZIONE
Objective of the study
The objective of the study is to confirm that treatment with BNT324 is clinically superior to standard chemotherapy alone.
Prostate Cancer.
Pathologies
Male urologic cancers (urological tumors)
Medication
BNT324 vs. Docetaxel
Who is eligible to participate in the study?
Patients who are 18 years of age or older and who meet the study’s eligibility criteria may participate in this study.
Patients who have received prior treatment.
View the full study Back to search page